REDWOOD CITY, Calif., May 2, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ("AcelRx"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported additional clinical results for its lead product candidate, the Sufentanil NanoTab PCA System for the treatment of moderate-to-severe acute pain in the hospital setting. These data are being presented in five posters at the American Society of Regional Anesthesia and Pain Medicine (ASRA) spring meeting held May 2 to May 5, 2013 in Boston, MA. New analyses from the Phase 3 comparison trial of the NanoTab System to intravenous patient-controlled analgesia (IV PCA) with morphine ( see press release dated November 15, 2012) demonstrate that sufentanil delivered via the NanoTab System has a significantly greater pain intensity reduction in the first four hours after starting treatment than IV PCA morphine (p<0.01). In addition, there were fewer patients throughout the study that experienced oxygen desaturation events below 95% in the Sufentanil NanoTab PCA System group than in the IV PCA morphine group (p=0.028). Oxygen saturation is a measure of a patient's respiratory function and can be affected negatively by opioids. A decrease in oxygen saturation can be linked to the serious adverse event of respiratory depression.
"Obtaining effective control over post-operative pain early on is critical not only for patient satisfaction, but to avoid the deleterious effects of under-treatment of pain, such as pulmonary complications and an increased stress response" remarked Marc Huntoon, MD, Professor and Chief, Division of Pain Medicine at Vanderbilt University in Nashville TN. "Providing rapid, effective analgesia following major surgery while reducing oxygen desaturation events is an important advance in treatment of post-operative pain," added Dr. Huntoon.
Four additional posters presented at the meeting highlighted recently released results from a placebo-controlled Phase 3 study conducted in abdominal surgery patients, new pharmacokinetic data from a study evaluating different oral-transmucosal routes of delivery of sufentanil NanoTabs, design features for the NanoTab System, and new data from three Human Factors studies describing ease of set-up and use of the NanoTab System for patients and healthcare personnel.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts